Lotus Pharmaceuticals, Inc., has advanced in the development of a treatment for Hepatitis B and also increased its number of local outlets to 15 retail stores. China offers a huge pool of subjects for study and a promising market for any resulting treatments. Asia is home to about three-quarters of the world’s liver cancers, caused largely by Hepatitis B infections.
The World Health Organization (WHO) recently noted around 500,000 people worldwide die of liver cancer each year. Up to 80% of the cases are related to hepatitis B, said the World Health Organization that warned that hepatitis B will result to cirrhosis and liver cancer and consider vaccination the best remedy to prevent infection with the dangerous disease.
These infections are common in Southeast Asia and Hong Kong, often leading to liver cirrhosis and cancer. According to the Hong Kong Cancer Registry’s latest statistics, liver cancer was the fourth most common cancer in 2004 and the third most common cause of cancer deaths. That year, 1,663 new cases were registered and 1,417 people died from liver cancer. The crude death rate was 20.6 per 100,000 population.
Liver cancer is about three times more common in men than in women in Hong Kong. And it’s closely related to hepatitis B infection (rather than drug or alcohol-related liver toxicity).
About 12 million Vietnamese people or 14% of the country’s population are now suffering from hepatitis B, said Prof. Pham Hoang Phiet, Vice Chairman of Vietnam Liver and Gall Association. Of the sum, about three million patients are badly in need of treatment, he added.
Hepatitis B is Deadly in Some Cases and in Others Extremely Debilitating – Treatment is Crucial
Hepatitis B virus (HBV) is a disease that leads to inflammation of liver cells (hepatocytes). It may also be caused by chemical poisons such as alcohol, aflatoxins, drugs and by other parasites and infectious agents such as amoeba and bacteria. There are five versions of viral hepatitis but the most fatal is HBV.
Hepatitis B virus is a member of the hepadnavirus family, which includes DNA viruses that cause hepatitis in birds and mammals. The virus particle consists of a sphere with a core surrounding the viral DNA. Viral hepatitis B may either appear without symptoms, acute, fulminant or chronic, leading to liver cancer.
There are over 4 million clinical cases of acute hepatitis every year worldwide. 25 percent of the 1 million infected people become carriers of the disease. There are more than 2 billion people infected with HBV worldwide and 250 million remain chronically infected carriers.
Hepatitis B virus (HBV) is prevalent throughout the world with high prevalence in Africa, Asia, southern Europe, and Latin America, where more than half of the population is infected during their lifetime, yet 2 – 20 percent are chronic carriers. In comparison to the developed world, where the prevalence of chronic HBV infection is less than 1 percent.
Hepatitis B early symptoms are fever and loss of appetite. The symptoms progressively turn to yellow eyes, abdominal pains, on and off diarrhea and accumulated water in the abdomen within 2-6 weeks of infection. In some patients it can become more severe and may lead to liver failure. When Hepatitis B disease reaches the stage of organ failure, it will be followed by death.
In the first stage, 50-60 percent of those infected recover, while 25-30 percent become carriers. Generally less than 2 percent progress to death.
Lotus, Inc. is well established in China in R&D for Hepatitis B. While Genesis works on the treatment, its retail pharmacies are quickly becoming established and generating revenue for the R&D arm of the company! This is a clever way to finance the Research and Development demands for a new medical treatment.
GTEC has with this combination of companies demonstrated its very focused approach to cash flow and revenue!
Genesis Technology Group, Inc. Boca Corporate Plaza
7900 Glades Road, Suite 420
Boca Raton, FL 33434
Phone: (561) 988-9880
Fax: (561) 988-9890
Email: General Information: info@genesis-china.net
Investor relations: clinton@genesis-china.net
Disclosure: Pentony Enterprises LLC has been compensated $3,600 and 265,000 restricted shares directly from the company for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.
Forward Looking Statement: Certain sections of this report may contains forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, aircraft production, deliveries and backlog stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors, including, without limitation:
General and international political and economic conditions; All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. The company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com.
